The SYK inhibitor entospletinib in combination with obinutuzumab downregulates the expression of PD-1 in CD4+ and CD8+ T-cell subsets of CLL patients, partially reversing the T-cell exhausted phenotype (98). This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.